In its 31 years of bringing together health-care industry executives, investors and entrepreneurs, the J.P. Morgan Healthcare Conference has become a top venue for deal making.
It’s also a place where you’ll hear plenty of complaints about industry woes, including the ongoing recession and the bureaucratic inefficiency of regulatory agencies.
But this year, some in the industry–especially biotech investors–are much more upbeat, saying 2013 will a time when promising new technologies will get the funding they need for development and eventual commercialization.
To read the original article: Life-Science Investors See Biotech Among Quality Prospects This Year - Venture Capital Dispatch - WSJ
